Key Highlights

  • 13.26% is the pre-market decline indicated for Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) on November 17, 2026, with shares indicated at USD 1.40 against a calculated prior close of USD 1.6140.
  • 1.17 million shares were outstanding in the latest published data, implying a calculated market Capitalization of about USD 1.64 million at the indicated pre-market price of USD 1.40 per share.
  • 13.43 million USD was trailing revenue, down 33.9% from USD 20.31 million, against a trailing net loss of USD 1.14 million, or USD 1.39 per share, in the latest published data.
  • 95.48% is the calculated decline from the 52-week high of USD 30.96 to the indicated price, with a 52-week low of USD 1.628 now sitting above the indicated level for Cellyan shares.

What Moved Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) in Pre-Market Trading on November 17, 2026 (-USD 0.2140, -13.26%)

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) is indicated at USD 1.40 in pre-market trading on Tuesday, November 17, 2026, a pre-market move of -13.26%. The calculated prior close is USD 1.6140 (price divided by 0.8674) and the calculated USD move is -USD 0.2140. With 1.17 million shares outstanding, the calculated market capitalization is about USD 1.64 million.

The Rationale: Reverse Split and Bid Price Deficiency Context for Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD)

No company release or filing dated November 17, 2026 was identified in published coverage, so the move is not attributed to a specific event. As general context, the company announced a 1-for-20 consolidation of its Class A and Class B ordinary shares on October 21, 2026. It received a Nasdaq bid price deficiency notice on January 16, 2026 and a grace period notice on July 16, 2026. Shareholders approved a restructuring on December 12, 2025 that renamed the company and raised authorized shares from 100 million to 1 billion, split into 940 million Class A and 60 million Class B. Published coverage also noted a Trading halt pending news.

Valuation, Liquidity and Risks for Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD)

Trailing Revenue was USD 13.43 million, down 33.9% from USD 20.31 million, with a trailing net loss of USD 1.14 million, or USD 1.39 per share. The 52-week range runs from USD 1.628 to USD 30.96. Cash and Debt figures were not found. The company filed a USD 200 million mixed securities shelf and a resale registration of 12.5 million Class A shares for a holder, and the tenfold rise in authorized shares leaves room for dilution. With a calculated Market Value under USD 100 million, this is a nano-cap with elevated dilution, listing-compliance and Volatility risk, and the very small share count can leave trading thin.

Where Things Stand

The indicated pre-market price of USD 1.40 for Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) is 13.26% below a calculated prior close of USD 1.6140 on November 17, 2026. The company has about 1.17 million shares, a calculated market value near USD 1.64 million, trailing revenue of USD 13.43 million and a trailing net loss of USD 1.14 million. A 1-for-20 consolidation announced on October 21, 2026 and Nasdaq notices dated January 16, 2026 and July 16, 2026 frame the listing backdrop. No same-day catalyst was identified, so thin liquidity and low-priced volatility are general context rather than established causes. Pre-market quotes are indicative until the 9:30 a.m. ET open.